Retinoic acid plus arsenic trioxide, the ultimate panacea for acute promyelocytic leukemia?

  • Lallemand-Breitenbach V
  • de The H
  • 4


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


Rarely in the field of cancer treatment did we experience as many surprises as with acute promyelocytic leukemia (APL). Yet, the latest clinical trial reported by Lo-Coco et al in the New England Journal of Medicine is a practice-changing study, as it reports a very favorable outcome of virtually all enrolled low-intermediate risk patients with APL without any DNA-damaging chemotherapy. Although predicted from previous small pilot studies, these elegant and stringently controlled results open a new era in leukemia therapy.

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • V. Lallemand-Breitenbach

  • H. de The

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free